[go: up one dir, main page]

WO1999051264A3 - Leishmania cysteine proteinases - Google Patents

Leishmania cysteine proteinases Download PDF

Info

Publication number
WO1999051264A3
WO1999051264A3 PCT/GB1999/000889 GB9900889W WO9951264A3 WO 1999051264 A3 WO1999051264 A3 WO 1999051264A3 GB 9900889 W GB9900889 W GB 9900889W WO 9951264 A3 WO9951264 A3 WO 9951264A3
Authority
WO
WIPO (PCT)
Prior art keywords
cysteine proteinases
leishmania
leishmania cysteine
leishmania vaccine
proteinases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1999/000889
Other languages
French (fr)
Other versions
WO1999051264A2 (en
Inventor
Jeremy Charles Mottram
Graham Herbert Coombs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Glasgow
Original Assignee
University of Glasgow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Glasgow filed Critical University of Glasgow
Priority to APAP/P/2000/001945A priority Critical patent/AP2000001945A0/en
Priority to IL13863999A priority patent/IL138639A0/en
Priority to BR9909388-0A priority patent/BR9909388A/en
Priority to EP99915864A priority patent/EP1067961A2/en
Publication of WO1999051264A2 publication Critical patent/WO1999051264A2/en
Publication of WO1999051264A3 publication Critical patent/WO1999051264A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The present invention relates to a Leishmania vaccine, more particularly a Leishmania vaccine comprising active or inactive cysteine proteinase(s), particularly in recombinant form, for use in immunising mammals, such as dogs and/or humans.
PCT/GB1999/000889 1998-04-03 1999-04-06 Leishmania cysteine proteinases Ceased WO1999051264A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
APAP/P/2000/001945A AP2000001945A0 (en) 1998-04-03 1999-04-06 Leishmania cysteine proteinases.
IL13863999A IL138639A0 (en) 1998-04-03 1999-04-06 Leishmania cysteine proteinases
BR9909388-0A BR9909388A (en) 1998-04-03 1999-04-06 Use of at least one leishmania cysteine proteinase, vaccine, protein lpa. infantum, genes cpa and cpb of l. infantum, cpa or cpb, and, use of the cpa and / or cpb proteins or the nucleic acid sequences of the cpa and / or cpb
EP99915864A EP1067961A2 (en) 1998-04-03 1999-04-06 Leishmania cysteine proteinases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9807293.7A GB9807293D0 (en) 1998-04-03 1998-04-03 Leishmania cysteine proteinases
GB9807293.7 1998-04-03

Publications (2)

Publication Number Publication Date
WO1999051264A2 WO1999051264A2 (en) 1999-10-14
WO1999051264A3 true WO1999051264A3 (en) 1999-12-09

Family

ID=10829885

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/000889 Ceased WO1999051264A2 (en) 1998-04-03 1999-04-06 Leishmania cysteine proteinases

Country Status (6)

Country Link
EP (1) EP1067961A2 (en)
AP (1) AP2000001945A0 (en)
BR (1) BR9909388A (en)
GB (1) GB9807293D0 (en)
IL (1) IL138639A0 (en)
WO (1) WO1999051264A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7736875B2 (en) 2000-09-08 2010-06-15 Prozymex A/S Dipeptidyl peptidase I crystal structure and its uses

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706930D0 (en) 1997-04-04 1997-05-21 Univ Glasgow Leishmania vaccine
GB0008903D0 (en) * 2000-04-12 2000-05-31 Univ Glasgow Stage-specific sequences
ATE378411T1 (en) * 2000-09-08 2007-11-15 Prozymex As RAT-SPECIFIC CATHEPSIN, DIPEPTIDYL PEPTIDASE I (DPPI): CRYSTAL STRUCTURE, INHIBITORS AND THEIR APPLICATIONS
US8865419B2 (en) 2008-07-04 2014-10-21 Institut De Recherche Pour Le Developpement (I.R.D.) Method for the screening of conserved secreted proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044943A1 (en) * 1997-04-04 1998-10-15 The University Court Of The University Of Glasgow Leishmania vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044943A1 (en) * 1997-04-04 1998-10-15 The University Court Of The University Of Glasgow Leishmania vaccine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BEYRODT C G ET AL: "Characterization of an antigen from Leishmania amazonensis amastigotes able to elicit protective responses in a murine model.", INFECTION AND IMMUNITY, (1997 JUN) 65 (6) 2052-9., XP002118939 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; OMARA-OPYENE A L ET AL: "Molecular cloning, characterization and overexpression of two distinct cysteine protease cDNAs from Leishmania donovani chagasi.", XP002118942, retrieved from STN Database accession no. 1998156761 *
MOLECULAR AND BIOCHEMICAL PARASITOLOGY, (1997 DEC 1) 90 (1) 247-67. *
MOTTRAM J.C. ET AL: "A developmetally regulated cysteine proteinase gene of Leishmania mexicana", MOLECULAR MICROBIOLOGY, vol. 6, no. 14, 1992, pages 1925 - 1932, XP002118941 *
SOUZA A. ET AL: "Characterization of a multi-copy gene for a major stage specific cysteine proteinase of Leishmania mexicana", FEBS LETTERS, vol. 311, no. 2, 1992, pages 124 - 127, XP002118940 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7736875B2 (en) 2000-09-08 2010-06-15 Prozymex A/S Dipeptidyl peptidase I crystal structure and its uses

Also Published As

Publication number Publication date
BR9909388A (en) 2000-12-05
GB9807293D0 (en) 1998-06-03
AP2000001945A0 (en) 2000-12-31
EP1067961A2 (en) 2001-01-17
WO1999051264A2 (en) 1999-10-14
IL138639A0 (en) 2001-10-31

Similar Documents

Publication Publication Date Title
MX265024B (en) Novel surfactants and formulations.
ATE289640T1 (en) AMIDOFUNCTIONAL AMINOPOLYDIORGANOSILOXANES
WO2002069846A3 (en) Embolic protection filter delivery sheath
AU2001257312A1 (en) Improved face mask structure
WO2002102586A3 (en) Cellulose-polymer composites and methods for manufacturing same
DE60120712D1 (en) Kallikrein gen
WO2001054659A3 (en) Slimming cosmetic composition comprising a plant extract containing a plant natriuretic peptide (pnp)
LT99131A (en) Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, acitivity
WO2001072264A3 (en) Pro-liposomal encapsulated preparations (iv)
MXPA03004563A (en) Surfactant systems for personal care products.
ZA200403803B (en) Selective targeting of apoptotic cells.
WO2002062304A3 (en) Cosmetic and/or pharmaceutical agents containing an acylated amino acid and a protein condensate
WO1999051264A3 (en) Leishmania cysteine proteinases
MXPA02002565A (en) Processes for making protein hydrolysates from animal peptone and for preserving mucosa.
AP9901666A0 (en) Leishmania vaccine.
WO2002046225A3 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
WO2004110469A3 (en) Formulations comprising factor viia and a factor vii related polypeptide
WO2002085930A3 (en) Immunomodulating agents from parasitic worms and method for isolation thereof
WO2002087604A8 (en) Preparations containing a combination of vitamin e and afamin
IL164901A0 (en) Optically active beta-aminoketones, optically active 1,3-aminoalcohols and processes for preparing them
MXPA03008099A (en) Topical composition comprising a 1, 2-heteroatom constituted diene cosmetic bonding agent.
AU3519299A (en) Human casb12 polypeptide, a serine protease
WO2002038122A3 (en) Compositions comprising at least a glycosidase, said compositions not comprising protease
WO2003020767A3 (en) Antibodies against caspase-8, their preparation and use
AU2002216617A1 (en) Cloning endangered and extinct species

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): BR IL MX US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): BR IL MX US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999915864

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 138639

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/009706

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 1999915864

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999915864

Country of ref document: EP